Quick Heal Technologies (QUICKHEAL) investor relations material

Executive summary

• Q2 FY27 net revenue was INR 64.9 Cr, up 44.3% QoQ and down 22.3% YoY; EBITDA was INR 2.3 Cr and PAT INR 5.8 Cr after Q1 losses.

• Strategy emphasizes commercial execution, enterprise cybersecurity and privacy, portfolio monetization, customer acquisition, and more selective investment.

• H1 strategic wins in Defense, BFSI and a large IT services account, plus government momentum, supported the enterprise push.

Financial highlights

• Q2 revenue was INR 64.9 Cr versus INR 83.5 Cr in Q2 FY26 and INR 45.0 Cr in Q1 FY27; H1 revenue was INR 109.92 Cr versus INR 140.75 Cr.

• Q2 EBITDA was INR 2.3 Cr versus INR 9.2 Cr in Q2 FY26 and a Q1 loss of INR 17.6 Cr; EBIT was a loss of INR 3.5 Cr.

• Q2 PAT was INR 5.8 Cr versus INR 7.9 Cr in Q2 FY26 and a Q1 loss of INR 5.3 Cr; diluted EPS was INR 1.0.

• H1 FY27 EBITDA was a loss of INR 15.3 Cr versus a loss of INR 0.5 Cr; PAT was INR 0.52 Cr versus INR 2.4 Cr.

• Q2 expenditure excluding depreciation was flat at INR 63 Cr.

Outlook and guidance

• Enterprise is expected to exceed 80% of revenue contribution within three years, from almost 56% currently; management framed this as an expectation, not formal guidance.

• Priorities include moving upmarket, targeting large and mid-market enterprises, sharpening go-to-market execution, and scaling the holistic product stack as customer validation grows.

• Investments include EDR, XDR, Zero Trust, data privacy, government penetration, international expansion, and DRPS/RRaaS offerings.

• Data privacy is viewed as a significant medium- to long-term growth driver and expected to approach endpoint security in scale soon.

• International expansion will be selective, focused on building meaningful positions in chosen markets.